Wednesday, July 8, 2026

pharma · Metastatic Pancreatic Adenocarcinoma · Primary Biliary Cholangitis

Ipsen

Ipsen clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

70, Rue Balard, Paris, Île-de-France 75015, FR HQ
6,584 Employees
NMPA registrant Type
Company details
Status
Public
HQ
70, Rue Balard, Paris, Île-de-France 75015, FR
Employees
6,584
Programs
27
Drugs
36
Patents
0
Intelligence · Clinical Programs

Ipsen projects

3 ClinicalTrials.gov programs sponsored by Ipsen.

Ipsen has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. A Mass Balance Study of [14C]-IPN60250 in Healthy Adult Participants

    Ipsen

    Primary sclerosing cholangitis (PSC)

    phase 1 other active

    1 trial
  2. CLIN-60250-450

    Ipsen

    Not applicable

    phase 1 other active

    1 trial
  3. D-FR-60010-015

    Ipsen

    Metastatic Pancreatic Adenocarcinoma

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does Ipsen have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.